
|Videos|October 31, 2015
How the FDA Views Compounding
Ronna B. Hauser, PharmD, vice president of pharmacy affairs for the National Community Pharmacists Association (NCPA), talks about the current position of the FDA regarding compounding.
Advertisement
Ronna B. Hauser, PharmD, vice president of pharmacy affairs for the National Community Pharmacists Association (NCPA), talks about the current position of the FDA regarding compounding.
This video was recorded at the 2015 NCPA Annual Convention.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Implementing Enfortumab Vedotin-ejfv Plus Pembrolizumab: Navigating Safety Data and the Pharmacist’s Role
2
Improving Outcomes in Diffuse B-Cell Lymphoma Requires Multidisciplinary Evolution
3
Long-Term BENEFIT Data Affirm Isa-VRd as Standard of Care in Transplant-Ineligible NDMM
4
Daratumumab Boosts Depth and Durability of Response After ASCT, Offering Clear Guidance for Pharmacist Counseling
5

















































































































































































































